Japanese Type 2 Diabetes Treatment Persistence Claims Analysis 2017-2023

A study of 255,974 Japanese patients with type 2 diabetes prescribed fixed-dose combination therapies based on dipeptidyl peptidase-4 inhibitors. It analyzes treatment persistence probabilities and median duration across three drug combination categories using hospital-based claims data from 2017 to 2023.

Use Cases

• Analyze treatment persistence probability over time for DPP-4i/metformin, DPP-4i/SGLT2i, and DPP-4i/TZD categories.
• Compare median treatment duration across the three fixed-dose combination categories using claims data.
• Model discontinuation hazard ratios, such as for DPP-4i/SGLT2i versus DPP-4i/metformin.
• Investigate associations between patient factors like age or comorbidities (e.g., metastatic cancer) and treatment discontinuation or switching.

Strengths

• Analysis of 255,974 patient records from a large hospital-based claims database.
• Covers a 6-year time range from 2017 to 2023.
• Provides specific metrics like median treatment duration (e.g., 503 days for DPP-4i/SGLT2i) and persistence probabilities at 500 and 1500 days.

Limitations

• Data is limited to a hospital-based claims database in Japan, which may not represent the broader national or global population.
• The dataset's underlying structure, column names, and sample data are not provided, limiting direct analytical use.
• Primary files are document formats (DOCX, PDF, EPS), not structured data files, requiring significant extraction effort.

Provenance

Source

figshare

Collection Method

Noninterventional study using a large hospital-based claims database.

Time Range

2017 to 2023

Freshness

null

Geography

Japan